Tajikistan Medical Device Registration Dossier: Structure and Submission Requirements Under Law No. 1893

1. Key takeaways

For the submission stage of a medical device registration dossier in Tajikistan, the law establishes only three elements: who submits, to whom, and in what form. Article 17(2) of Law No. 1893 provides that, for the registration of medicines, medical products and quasi-medicinal products, the manufacturer or its authorized person (the applicant) must submit the prescribed list of necessary documents to the State Supervisory Authority for Pharmaceutical Activities in electronic or written form. GRZAN notes that the legal text does not directly set out the contents of the document list; the list itself is developed and approved by the authorized state body in the healthcare sector under Article 17(12). Accordingly, the skeleton of a registration dossier should be built along two parallel lines: the elements defined by the law and the checklist issued in the procedural documents of the Ministry of Health. Because the procedural framework can change, companies must treat the dossier structure as a dynamic requirement that is reconfirmed at the start of every project rather than a fixed template.

2. Legal basis

3. Expert insights

Insight 1: Article 17(2) leaves the determination of the document list to procedural documents, which means the dossier structure is changeable. The provision refers to a prescribed list of necessary documents, and the word prescribed points to the procedural documents that the Ministry of Health is authorized to develop under Article 17(12). The GRZAN conclusion is that Tajikistan has no stable, statutory-level registration document checklist. Companies must re-request the currently valid procedural documents at the start of every project and cannot rely on historical templates, because the list content, formatting and sequencing may all be updated between submissions.

Insight 2: The dossier skeleton should be built in reverse from the five-dimensional standard of Article 18(1). Since expert review proceeds along the five dimensions of safety, quality, effectiveness, economic considerations and risk, the dossier structure should mirror them. GRZAN recommends the following skeleton: an administrative volume (corporate status, authorization, proof of origin), a safety volume (biological interaction evaluation, risk analysis), a quality volume (quality system evidence, quality control specification documents, standards list), an effectiveness volume (technical testing, clinical evidence, clinical laboratory verification), and an economic volume (cost and accessibility justification). This structure maps one-to-one onto the three categories of evidence in Article 33 and the five-dimensional standard of Article 18.

Insight 3: The equal validity of electronic and paper submission opens space for digitalization but also creates uncertainty. Article 17(2) permits both forms, yet the law does not prescribe technical specifications for electronic submission. The GRZAN practical approach is to confirm in writing with the supervisory authority, before submission, the currently acceptable electronic submission channel, format and electronic signature requirements, and to retain the confirmation record; where confirmation cannot be obtained, submit on paper and request a signed receipt. This written record becomes valuable evidence if the authority later questions the admissibility of the submission.

Insight 4: A confidentiality determination under Article 17(7) should be requested together with the submission. This paragraph allows information on registered products to be recognized as confidential where the formulation or composition should not be known to industry peers and the manufacturer must keep it secret, or where confidentiality is determined by its commercial value. The request should be filed at submission time, not after registration is completed. GRZAN recommends including a separate statement of the scope of confidential information in the dossier, listing field by field the items for which confidentiality is sought and identifying which statutory condition each item satisfies.

Insight 5: The separate tracks of Article 17(10) and Article 17(12) require companies to request the medical product version of the procedural documents. Paragraph 10 covers medicines, while paragraph 12 covers medical products and quasi-medicinal products. This separation recurs throughout the law (the same logic appears in Article 18(2) and in Article 34(8) and 34(10)), showing that the legislator deliberately made device procedures independent. When requesting documents, companies should explicitly reference medical products to avoid receiving the inapplicable medicines version, which could mislead the entire dossier build.

4. Practical recommendations

1. Re-request the procedural documents at the start of every project. GRZAN recommends making the request for currently valid medical product registration procedural documents the first milestone of project initiation, with formal version logging, rather than reusing historical templates that may no longer reflect the current requirements.
2. Build the dossier skeleton in reverse from the five-dimensional standard. Organize the dossier into the five main volumes of safety, quality, effectiveness, economic considerations and risk, and place a review-dimension index table at the front of the dossier so reviewers can locate each dimension quickly.
3. Confirm the submission form in writing before filing. Under Article 17(2), confirm with the supervisory authority the channel, format and signature requirements for electronic submission and retain the confirmation record; where confirmation is unavailable, submit on paper and obtain a signed receipt.
4. File the confidentiality request simultaneously with submission. Under Article 17(7), submit the statement of the scope of confidential information together with the dossier, listing each field for which confidentiality is claimed and the corresponding statutory condition it meets.
5. Explicitly request the medical product version of the documents. Under Article 17(12), clearly state that the requested procedures apply to medical products and quasi-medicinal products, distinguishing them from the medicines version under Article 17(10).

5. Verification checklist

• □ Currently valid medical product registration procedural documents have been obtained and version-logged (Article 17(12))
• □ The dossier skeleton has been built to the five-dimensional standard of Article 18(1) with a review-dimension index table
• □ The submitting entity is confirmed as the manufacturer or its authorized person (Article 17(2))
• □ The currently acceptable submission form (electronic or paper) and technical requirements have been confirmed in writing
• □ The statement of the scope of confidential information under Article 17(7) has been filed together with the submission
• □ The procedural documents obtained are confirmed as the medical product version, not the medicines version
• □ A signed receipt or electronic submission acknowledgement has been obtained

Regulatory information verified as of October 29, 2026.

In the Central Asian market, GRZAN focuses its core capabilities on three areas. First, distinguishing the different legal positions of each market within the Eurasian Economic Union: Kazakhstan and Kyrgyzstan are full member states where a national track and a Union track coexist; Uzbekistan is an observer state with only the national track; Tajikistan and Turkmenistan lie outside the Union framework and must proceed entirely under national procedures. Second, local authorized representative services: GRZAN acts as the statutory representative of manufacturers in these countries, undertaking registration submission, regulatory communication and post-market reporting obligations. Third, quality system and testing support: GRZAN helps establish a quality management system compliant with ISO 13485 and connects clients with locally accredited laboratory resources.

Business inquiries: info@grzanglobal.com